Primary lung sarcoma treated with stereotactic ablative radiotherapy: a case report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yeo, Seung-Gu | - |
dc.date.accessioned | 2021-08-11T16:24:27Z | - |
dc.date.available | 2021-08-11T16:24:27Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1178-6930 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8435 | - |
dc.description.abstract | Primary lung sarcoma (PLS) is an extremely rare, very aggressive malignancy. Surgical removal is considered the treatment of choice, and patients who have been given conventional radiotherapy have had inferior outcomes. This study is the first describing a case of PLS treated with stereotactic ablative radiotherapy (SABR), which precisely targets a small tumor with a markedly higher biologically effective dose than conventional radiotherapy. The patient was an 82-year-old man who was diagnosed with primary lung leiomyosarcoma based on radiology, pathology, and immunohistochemical examinations. The PLS was located in the right lower lobe and measured 2.5 cm. No regional nodal or distant organ metastasis was observed. He was inoperable medically. The SABR was performed using volumetric modulated arc therapy and a dose of 56 Gy in four fractions. Follow-up computed tomography 2 months after SABR revealed a complete tumor response. The toxicity was limited to mild respiratory symptoms. The patient is alive and has had no evidence of disease for 2 years. This study suggests that SABR can be a safe and effective treatment option for PLS. | - |
dc.format.extent | 4 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Dove Medical Press Ltd | - |
dc.title | Primary lung sarcoma treated with stereotactic ablative radiotherapy: a case report | - |
dc.type | Article | - |
dc.publisher.location | 뉴질랜드 | - |
dc.identifier.doi | 10.2147/OTT.S138595 | - |
dc.identifier.scopusid | 2-s2.0-85021993478 | - |
dc.identifier.wosid | 000404878800001 | - |
dc.identifier.bibliographicCitation | OncoTargets and Therapy, v.10, pp 3285 - 3288 | - |
dc.citation.title | OncoTargets and Therapy | - |
dc.citation.volume | 10 | - |
dc.citation.startPage | 3285 | - |
dc.citation.endPage | 3288 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | BODY RADIATION-THERAPY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | METASTASES | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordAuthor | primary lung sarcoma | - |
dc.subject.keywordAuthor | leiomyosarcoma | - |
dc.subject.keywordAuthor | stereotactic ablative radiotherapy | - |
dc.subject.keywordAuthor | stereotactic body radiotherapy | - |
dc.subject.keywordAuthor | radiation therapy | - |
dc.subject.keywordAuthor | sarcoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.